THIRD TEAM David Risinger Morgan Stanley
David Risinger of Morgan Stanley drops one notch to No. 3 but continues to win favor from clients because he “speaks his mind and pulls no punches,” as one money manager puts it. Risinger upgraded Bristol-Myers Squibb Co. in June, at $27.42, on news that apixaban — a blood-thinner medication the New York–based company developed with crosstown rival Pfizer — had proved to be more effective than market-leader warfarin in a Phase 3 atrial fibrillation study. The stock had advanced 8.5 percent, to $29.75, by the end of August, beating the sector by 11.2 percentage points.